Reinforced adhesive complex coacervates and methods of making and using thereof
US-2016250375-A1 · Sep 1, 2016 · US
US9913927B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9913927-B2 |
| Application number | US-201515325885-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 14, 2015 |
| Priority date | Jul 14, 2014 |
| Publication date | Mar 13, 2018 |
| Grant date | Mar 13, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications.
Opening claim text (preview).
What is claimed: 1. A method for reducing or inhibiting blood flow in a blood vessel of the subject comprising introducing into the vessel an adhesive fluid complex coacervate comprising at least one polycation, at least one polyanion, and a monovalent salt, wherein the concentration of the monovalent salt selected from the group consisting of NaCl, KCl, and mixtures thereof in the adhesive fluid complex coacervate is greater than the concentration of the monovalent salt in the blood vessel of the subject, whereupon introduction of the adhesive fluid complex coacervate into the vessel the adhesive fluid complex coacervate is converted to a solid in situ that creates an artificial embolus within the vessel. 2. The method of claim 1 , wherein the method reduces or inhibits blood flow to a tumor, an aneurysm, a varicose vein, an arteriovenous malformation, or a bleeding wound. 3. The method of claim 1 , wherein the method reinforces the inner wall of a blood vessel in the subject comprising introducing into the vessel the fluid complex coacervate. 4. The method of claim 1 , wherein the concentration of the monovalent salt in the complex coacervate is 1.5 to 10 times greater than the concentration of the monovalent salt in the aqueous environment. 5. The method of claim 1 , wherein the monovalent salt in the complex coacervate is NaCl. 6. The method of claim 1 , wherein the total positive/negative charge ratio of the polycation to the polyanion is from 4 to 0.25 and the concentration of the monovalent salt in the complex coacervate is from 0.5 M to 2.0 M. 7. The method of claim 1 , wherein the adhesive fluid complex coacervate has a pH of 6 to 9. 8. The method of claim 1 , wherein the polycation comprises a polyamino compound, wherein the polyamino compound comprises a natural polymer or a synthetic polymer having two or more guanidinyl sidechains. 9. The method of claim 1 , wherein the polycation comprises a polyacrylate comprising two or more pendant amino groups. 10. The method of claim 9 , wherein the amino group comprises an alkylamino group, a heteroaryl group, a guanidinyl group, an imidazole, or an aromatic group substituted with one or more amino groups, a primary amino group, a secondary amino group, tertiary amino group, or a quaternary amine. 11. The method of claim 1 , wherein the polycation is synthetic polyguanidinyl polymer comprising an acrylate, methacrylate, acrylamide, or methacrylamide backbone and two or more guanidinyl groups pendant to the backbone. 12. The method of claim 1 , wherein the polycation is a synthetic polyguanidinyl polymer comprising the polymerization product between a monomer selected from the group consisting of an acrylate, a methacrylate, an acrylamide, a methacrylamide, or any combination thereof and a compound of formula I wherein R 1 is hydrogen or an alkyl group, X is oxygen or NR 5 , where R 5 is hydrogen or an alkyl group, and m is from 1 to 10, or the pharmaceutically-acceptable salt thereof. 13. The method of claim 12 , wherein the polycation comprises polymerization product between the compound of formula I and methacrylamide. 14. The method of claim 12 , wherein R 1 is methyl, X is NH, m is 3. 15. The method of claim 1 , wherein the polyanion comprises a polyphosphate. 16. The method of claim 1 , wherein the polyanion is an inorganic polyphosphate or a phosphorylated sugar. 17. The method of claim 1 , wherein the polyanion comprises a hexametaphosphate salt. 18. The method of claim 1 , wherein the polyanion is inositol hexaphosphate. 19. The method of claim 1 , wherein the polyanion comprises a polyacrylate comprising two or more pendant phosphate groups. 20. The method of claim 1 , wherein the polyanion is the copolymerization product between a phosphate or phosphonate acrylate and/or phosphate or phosphonate methacrylate with one or more additional polymerizable monomers. 21. The method of claim 1 , wherein the adhesive fluid complex coacervate further comprises a contrast agent or a visualization agent. 22. The method of claim 21 , wherein the contrast agent comprises tantalum particles, gold particles, or an iodine complex. 23. The method of claim 1 , wherein the adhesive fluid complex coacervate further comprises a reinforcing component. 24. The method of claim 23 , wherein the reinforcing component comprises natural or synthetic fibers, water-insoluble filler particles, a nanoparticle, or a microparticle. 25. The method of claim 1 , wherein the adhesive fluid coacervate further comprises one or more bioactive agents. 26. The method of claim 25 , wherein the bioactive agent comprises an antibiotic, a pain reliever, an immune modulator, a growth factor, an enzyme inhibitor, a hormone, a mediator, a messenger molecule, a cell signaling molecule, a receptor agonist, an oncolytic, a chemotherapy agent, a receptor antagonist, a nucleic acid, or any combination thereof. 27. The method of claim 1 , wherein the polycation is a synthetic polyguanidino polymer comprising the polymerization product between a monomer selected from the group consisting of an acrylate, a methacrylate, an acrylamide, a methacrylamide, or any combination thereof and a compound of formula I wherein R 1 is hydrogen or an alkyl group, X is oxygen or NR 5 , where R 5 is hydrogen or an alkyl group, and m is 3, or the pharmaceutically-acceptable salt thereof, the polyanion comprises sodium hexametaphosphate, the total positive/negative charge ratio of the polycation solution to the polyanion is from 0.95 to 1.10 and the concentration of NaCl in the adhesive fluid complex coacervate is from 0.5 M to 2.0 M.
Gelatin · CPC title
Macromolecular compounds, i.e. oligomers, polymers, dendrimers · CPC title
Fluorescein, used in vivo · CPC title
Radioisotopes, radionuclides · CPC title
Materials resorbable by the body · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.